National News

New Regulatory Regime for 8 Medical Items under Drugs and Cosmetics Act

Transition time of 6 months allowed for ensuring supply chain continuity and access while implementing their regulatory order under Medical Devices Rules (2017)

Posted On: 18 APR 2021 7:05PM by PIB Delhi

Adopting a proactive and sensitive approach to address the needs of the Indian Industry, the Union Ministry of Health & Family Welfare has taken a significant decision for ensuring continued access of eight regulated medical devices today.

The Ministry had earlier notified the following medical items to be regulated under the Drugs and Cosmetics Act which was to come into effect from 1st April, 2021 (as per S.O. 775(E) dated 08th February, 2019 under Medical Devices Rules 2017):

  1. All Implantable Medical Devices;
  2. CT scan equipment;
  3. MRI equipment;
  4. Defibrillators;
  5. PET Equipment;
  6. Dialysis Machine;
  7. X-Ray Machine; and
  8. Bone marrow cell separator.

Accordingly, as per the said order the importers/manufacturers are required to take import/manufacturing licence from Central Licencing Authority or State Licencing Authority, as the case may be, for import/manufacture of above devices, w.e.f. 1st April, 2021.

In order to ensure  supply chain continuity and access to these Medical Devices, while implementing  smooth transition into the new regulatory regime, Union Ministry of Health and Family Welfare has now decided that in case an existing importer/manufacturer who is already importing /manufacturing any of these devices, has submitted application to Central Licencing Authority or State Licencing Authority, as the case may be, for grant of import /manufacturing licence in respect of the said device(s) under the provisions of MDR, 2017, the said application shall be deemed valid and the importer/manufacturer can continue to import /manufacture the said device(s) up to 6 months from issue of this order or till the time, the Central Licencing Authority or State Licencing Authority, as the case may be, takes a decision on the said application, whichever is earlier. Order in this regard has been issued by Drugs Controller General (India) on 18th April 2021 through CDSCO website.

****

Also See:

newsonline

Recent Posts

Salesforce Brings The First Edition of Agentforce World Tour To Delhi

Salesforce, the worlds #1 CRM, powered by AI technology and capabilities, today hosted India's first…

13 hours ago

Metropolis Healthcare unveils Key Findings from Molecular Genomics Study in honour of Lung Cancer Awareness Month

Lung cancer remains one of the most prevalent and deadly cancers globally, with approximately 2.2…

13 hours ago

Sachidanand Upadhyay: A Visionary Leader Dedicated to Building Better Tomorrow

At Lord's Mark Industries Limited, led by Sachidanand Upadhyay, we are committed to fostering positive…

14 hours ago

HDFC Life Launches ‘The Missing Beat – Second Chance’

After the success of the first phase of 'The Missing Beat', a campaign aimed at…

14 hours ago

Raghu Vamsi Aerospace Group Lays Foundation Stone to Build New Facility in Hyderabad with the Investment of Rs.300 Crore

Laid the foundation stone by Shri D. Sridhar Babu, Minister of IT, Electronics, Communications, Industries…

14 hours ago

Global Recognition for Chitkara University in Times Higher Education Interdisciplinary Science Rankings 2025

Chitkara University has earned a prominent place on the global academic stage, ranking 161st in…

14 hours ago